WE AIM FOR AN ACTIVE LIFESTYLE AND IMPROVED QUALITY OF LIFE FOR THE MILLIONS AFFECTED BY CHRONIC INFLAMMATORY DISEASES
MORE ABOUT US

WE DEVELOP AN ANTI-INFLAMMATORY DRUG WITH FIRST-IN-CLASS POTENTIAL

We aim to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers the quality of life for millions.

Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis.

Our biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use.

THE STORY BEHIND LIPUM

Lipum was originally founded based on a discovery made by sci­entists at Umeå University.

The history of the innovation goes back 25 years when Olle Hernell, Prof. of Pediatrics, and his group was studying the nutrition of breast milk in newborns during early infancy, focusing on a protein that is now known as bile salt-stimulated lipase (BSSL).

Read more
For privacy reasons YouTube needs your permission to be loaded.
I Accept

BIOSTOCK INVESTOR MEETING

CEO Einar Pontén presents Lipum and the progress of ongoing clinical trials.

Watch on Youtube »

SUBSCRIBE TO INFORMATION FROM LIPUM

PRESS RELEASES

2023-09-13 08:45 Lipum to participate in following upcoming
Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming...
2023-08-31 08:00 Lipum AB – interim report for the period January-June 2023 Regulatory
Lipum AB (publ) has published the interim report for period January to June for 2023. Below is a summary, a complete report (only in Swedish) is available...
2023-08-14 07:30 PLOS ONE publishes results that highlights the role of BSSL in inflammatory joint disorders
Lipum AB (publ) today reported that the scientific publication titled “Effects of bile salt-stimulated lipase on blood cells and associations with...